DMKC Advisory Services LLC Increases Stake in Abbott Laboratories $ABT

DMKC Advisory Services LLC raised its position in Abbott Laboratories (NYSE:ABT) by 88.1% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 29,289 shares of the healthcare product maker’s stock after purchasing an additional 13,721 shares during the period. Abbott Laboratories accounts for approximately 2.1% of DMKC Advisory Services LLC’s portfolio, making the stock its 16th biggest holding. DMKC Advisory Services LLC’s holdings in Abbott Laboratories were worth $3,984,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth $30,000. JCIC Asset Management Inc. purchased a new stake in shares of Abbott Laboratories in the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC purchased a new stake in shares of Abbott Laboratories in the first quarter valued at about $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT opened at $133.53 on Thursday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a market cap of $232.39 billion, a price-to-earnings ratio of 16.73, a PEG ratio of 2.54 and a beta of 0.69. The stock’s 50-day moving average price is $131.63 and its 200 day moving average price is $131.24. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of several recent analyst reports. Evercore ISI boosted their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and raised their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Leerink Partners began coverage on Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 target price for the company. BTIG Research lowered their price target on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Finally, Raymond James Financial decreased their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.39.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.